Lupus & antiphospholipid syndrome
Anti-dsDNA IgE: a potential non-invasive test for prediction of lupus nephritis relapse
Authors' conclusion
These results suggest blood anti-dsDNA IgE as a non-invasive predictive marker of LN relapse.
Study context
- Population
- Patients with class III or IV±V lupus nephritis (LN) with active lesions, randomised to continuation or discontinuation of maintenance immunosuppressive therapy (MIST) after 2–3 years, with serum available at randomisation12 biopsy-proven relapses
- Participants
- 52 patients
- Comparison
- Anti-dsDNA IgE above vs below 1.9 arbitrary units for prediction of LN relapse
- Primary endpoint
- Biopsy-proven LN relapse (prediction by serum anti-dsDNA IgE)
- Follow-up
- 24 months
Methodological detailsprospective, controlled, biomarker study, Anti-dsDNA IgE and IgG quantified by ELISA in sera collected at randomisation; MIST continuation n=25, MIST discontinuation n=27
- Prospective
- Controlled
- Biomarker study
- Anti-dsDNA IgE and IgG quantified by ELISA in sera collected at randomisation; MIST continuation n=25, MIST discontinuation n=27
Primary result
As reported in the abstract
Survival without LN relapse
- Initial anti-dsDNA IgE levels higher in patients with subsequent LN relapse
- Anti-dsDNA IgG not associated with relapse
- Anti-dsDNA IgE >1.9 AU vs Anti-dsDNA IgE <1.9 AU: P = 0.019
Further findings
| Outcome | Values | P value |
|---|---|---|
| Survival without LN relapse, MIST discontinuation subgroupAnti-dsDNA IgE >1.9 AU vs Anti-dsDNA IgE <1.9 AU · lower relapse-free survival above threshold | P = 0.002 | |
| Prediction of severe LN relapse, all patients | Anti-dsDNA IgE >1.9 AU PPV 0.8 |
Original publication
Anti-dsDNA IgE: a potential non-invasive test for prediction of lupus nephritis relapse. RMD Open. Published 28 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →